How can we overcome ibrutinib resistance?
Why daratumumab will become key for the treatment of multiple myeloma
Lenalidomide maintenance – an active approach to treating MM?
Myeloma highlights from ASCO 2017
ENDEAVOUR, ASPIRE and TOURMALINE-MM1 trial results for multiple myeloma